Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement

Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission-induction in severe ANCA-associated vasculitis (AAV), but renal outcomes are unknown. This is a post hoc analysis of patients enrolled in the Rituximab for ANCA-Associated Vasculitis (RAVE) Trial w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Am Soc Nephrol
Hauptverfasser: Geetha, Duvuru, Specks, Ulrich, Stone, John H., Merkel, Peter A., Seo, Philip, Spiera, Robert, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G.M., St. Clair, E. William, Fessler, Barri J., Ding, Linna, Tchao, Nadia K., Ikle, David, Jepson, Brett, Brunetta, Paul, Fervenza, Fernando C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Nephrology 2015
Schlagworte:
Clinical Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378104/
https://ncbi.nlm.nih.gov/pubmed/25381429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2014010046
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge